Zimmer Biomet raises annual forecasts on knees and hips unit strength
Reuters
Published May 02, 2023 08:23AM ET
(Reuters) - Zimmer Biomet Holdings (NYSE:ZBH) Inc raised its annual sales and profit forecasts on Tuesday, banking on strong demand for its knees and hips products amid a sustained recovery in surgical procedures in the United States.
Shares of the Indiana-based medical device maker rose 3.72% to $144 before the bell, also buoyed by better-than-expected first-quarter results.
Zimmer Biomet's upbeat outlook comes after several medical device makers, including Stryker Corp (NYSE:SYK) and larger rival Abbott Laboratories (NYSE:ABT), raised their forecasts as easing staffing shortages at hospitals aid a recovery in medical procedures.
Zimmer Biomet, which offers products such as knee replacements and surgical robots, now expects a profit of $7.40 to $7.50 per share for 2023, compared with $6.95 and $7.15 per share previously forecast. Analysts on average were expecting a profit of $7.06 per share, according to Refinitiv data.
The company expects revenue to grow 5%-6% this year, compared with its previous forecast of 1.5%-3.5%.
"Investor focus is largely on Zimmer's ability to take a share in the knee and head market and the adoption of the company's new launches," BTIG analyst Ryan Zimmerman told Reuters before the results.
Analysts have highlighted that Zimmer's smart implant that was authorized by the U.S. health regulator in November for cementless knee replacement procedures will have a broad market opportunity.
The medical device maker's revenue rose 10% to $1.83 billion in the first quarter, beating analysts' average estimates of $1.70 billion.
Excluding items, the company made a profit of $1.89 per share for the quarter ended March 31, compared with analysts' estimates of $1.64 per share.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.